AMENDMENTS TO THE CLAIMS:

Please cancel claims 1-20 without prejudice.

Please add new claims 34-37.

Please amend claim 31 as follows:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-20 **(Cancelled)**

21. **(Previously presented)** A method for identifying an anti-cancer agent that modulates a biological activity of a gene product differentially expressed in a cancerous cell as compared to a normal cell, said method comprising:

contacting a candidate anti-cancer agent with a cell that expresses DKFZp5661133; and

detecting a difference between the biological activity of DKFZp5661133 in the presence and absence of the candidate anti-cancer agent, wherein a difference between the level of biological activity of DKFZp5661133 in the presence and absence of the candidate anti-cancer agent indicates that the candidate anti-cancer agent has anti-cancer activity.

22. **(Original)** The method of claim 21, wherein said cancerous cell and said normal cell are breast cells.

23. **(Previously presented)** The method of claim 21, wherein said detecting is by assessing expression of said gene product.

24. **(Original)** The method of claim 23, wherein expression is assessed by detecting a polynucleotide gene product.

25. **(Previously presented)** The method of claim 23, wherein expression is assessed by detecting a polypeptide gene product.

26. **(Previously presented)** The method of either of claim 21 or claim 32, wherein said candidate agent is selected from the group consisting of a small molecule, an antibody, an antisense polynucleotide, and an RNAi molecule.

27. **(Previously presented)** The method of claim 21, wherein said biological activity is modulation of a cancerous phenotype.

28. **(Original)** The method of claim 27, wherein said cancerous phenotype is abnormal cellular proliferation.

29. **(Previously presented)** The method of claim 27, wherein said cancerous phenotype is loss of contact inhibition.

Claim 30 **(Cancelled)**

31. **(Currently amended)** The method of either of claim 21 or claim 32 wherein the agent is a DKFZ antisense polynucleotide which inhibits DKFZ gene expression by at least 90% ~~comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:508 and SEQ ID NO:510~~.

32. **(Previously presented)** A method of screening a candidate agent for anti-cancer activity comprising:

(a) contacting a cell that expresses DKFZp5661133 with a candidate agent; and

(b) detecting a difference between the level of expression of DKFZp5661133 in the presence and absence of the candidate agent, wherein a difference between the level of DKFZp5661133 expression in the presence and in the absence of the candidate agent indicates that the candidate agent has anti-cancer activity.

33. **(Previously presented)** The method of claim 32 wherein a difference in expression levels of DKFZp5661133 is detected using a polymerase chain reaction, hybridization, or Western blot.

34. **(Previously presented)** The method of either of claims 21 or 32 wherein the cancer is breast cancer.

35. **(New)** The method of claim 31 wherein the DKFZ antisense polynucleotide comprises a nucleotide sequence comprising at least 12 contiguous nucleotides of SEQ ID NO:513, or complement thereof.

36. **(New)** The method of claim 31 wherein the DKFZ antisense polynucleotide comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:508 and SEQ ID NO:510.

37. **(New)** The method of claim 21 wherein the biological activity is selected from the group consisting of cell growth, proliferation and invasiveness.